Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Cytokine Release Syndrome 1Burkitt Lymphoma 1

Interventions

Dexamethasone 43Lenalidomide 26daratumumab 23Bortezomib 23pomalidomide 22Cyclophosphamide 16Specimen Handling 14Biopsy 14carfilzomib 13Magnetic Resonance Spectroscopy 11talquetamab 10iberdomide 9fludarabine 9Calcium Dobesilate 9isatuximab 8Melphalan 8belantamab mafodotin 7selinexor 5fludarabine phosphate 5X-Rays 5elotuzumab 4Whole-Body Irradiation 4Nuclear Medicine Department, Hospital 4trametinib 3tocilizumab 3dexamethasone acetate 3dexamethasone 21-phosphate 3dabrafenib 3auricularum 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × siltuximab × 30 days × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡